Consumer demand for sustainable proteins is skyrocketing, with plant-based alternatives and cellular agriculture gaining mainstream acceptance faster than most analysts predicted.
Venture capital investment in alternative proteins hit record levels in recent years, with regulators increasingly supporting innovations that address food security and environmental concerns.
From lab-grown meat to advanced agricultural systems, these companies are developing the technologies that could transform how we feed 10 billion people by 2050.
This collection focuses on the entire protein innovation ecosystem. We've identified companies addressing the sustainable food challenge from multiple angles - creating plant-based alternatives, developing lab-grown meat, and improving traditional agriculture with better fertilizers and animal health solutions.
This investment opportunity spans both established agricultural players and emerging food-tech innovators. The theme aims to capture value across the entire protein production chain, from agricultural inputs to finished food products, positioning investors to benefit from long-term shifts in how we produce protein.
These companies were selected based on their technological innovation, market position, and growth potential in addressing global food challenges. Our experts identified businesses poised to benefit from increased consumer demand for sustainable protein sources and the regulatory support accelerating this industry.
Looking to invest in the future of food? This carefully selected group of stocks represents companies solving our global protein challenges. From plant-based alternatives to agricultural innovation, these stocks have been thoughtfully chosen by our analysts for their potential in this growing market.
Summary of the Next-Gen Proteins basket market capitalisation and investor takeaways based on large-cap dominance.
BYND: $1.44B
OTLY: $482.24M
MOS: $9.26B
Erfahren Sie alles über diesen Aktienkorb. Lesen Sie unseren ausführlichen Artikel zu seinen Risiken und seinem Potenzial.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
+6
Gilead Sciences has secured FDA approval for a new once-daily HIV combination pill, streamlining therapy for millions of suppressed patients. This regulatory milestone spotlights investment opportunities in pioneering biopharmaceutical companies and drug delivery developers focused on advanced antiviral treatments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Here are a few of the assets in this group. Create an account to unlock the full list.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
Wenn Sie in diese Werte investieren:
In 12 Monaten könnte der Wert betragen:
+34.24%
Analysten erwarten im Durchschnitt, dass die Werte dieser Gruppe im nächsten Jahr um 34.24 % zulegen.
8 von 15 Werten dieser Gruppe werden von professionellen Analysten mit „Kaufen“ bewertet.
